Dr. Vishal Gandhi: Building India's Global Healthcare Hub

For years, the conversation around global health-tech innovation has centred on a handful of familiar hubs: the US, parts of Europe, Israel. India rarely makes that list, despite producing a steady stream of genuinely differentiated healthcare technology: diagnostics, devices, digital health platforms, and care-delivery models built for scale in ways few other markets can match.

The reason India hasn't broken into that conversation isn't a shortage of innovation. It's a shortage of platforms capable of carrying that innovation from a domestic Startup into a globally competitive company. Dr. Vishal Gandhi has spent the last several years trying to build exactly that platform.

Twenty-Seven Years to See the Whole Picture

As Founder & CEO of BIORx Venture Advisors, Chief Investment Officer at Indian Healthcare Angels, and Managing Partner at VEOCAP Ventures, Gandhi brings 27-plus years of experience across research, healthcare, venture building, investment banking, entrepreneurship, and Startup ecosystem development. It's a career built specifically to see the full arc a healthcare innovation has to travel: from a research finding, to a validated product, to an investable company, to a business capable of competing internationally.

That vantage point revealed a specific, persistent gap: Indian healthcare startups often had exceptional underlying technology but no clear path to the funding, business structuring, or global market access needed to compete on the world stage.

"This gap inspired me to establish BIORx Venture Advisors," Gandhi says, "with the vision of building an ecosystem where entrepreneurs receive not just capital but also strategic guidance, industry connections, and long-term support to transform innovation into successful businesses."

Why Global Ambitions Need Local Infrastructure First

Healthcare innovation is uniquely unforgiving of shortcuts. It demands specialized scientific and regulatory knowledge, moves through long development and validation cycles, and requires patient capital that understands those timelines rather than fighting them. Very few advisory firms combine deep healthcare-science literacy with genuine investment banking capability while also helping companies prepare for the complexities of cross-border growth.

BIORx was designed to close that gap end-to-end: sector-focused investment banking, venture building, fundraising, M&A advisory, commercialization support, and investor access with a strong focus on healthcare and life sciences. The firm's bet is straightforward: you can't build globally competitive Indian health-tech companies without first fixing the domestic infrastructure that determines whether promising technology ever becomes an investable business in the first place.

The Full-Stack Model Behind the Global Ambition

BIORx's service offering covers fundraising and capital advisory, mergers and acquisitions, venture building, commercialization strategy, financial and business advisory, valuation, investor readiness, strategic partnerships, and cross-border business expansion: the last of which sits at the centre of the firm's global positioning.

What sets the model apart, Gandhi says, is the combination of sector knowledge and transaction experience, combined with an active investor network anchored by Indian Healthcare Angels and VEOCAP Ventures, paired with a commitment to stay engaged with founders from idea stage through scale-up.

That continuity is what makes the eventual leap to global markets more structured rather than purely aspirational. Companies don't arrive at cross-border readiness by accident; they're built toward it over years of deliberate advisory support.

Building Institutional Credibility from Zero

None of this was handed to Gandhi. Building a specialized investment banking platform focused strongly on healthcare required earning the trust of entrepreneurs, investors, corporates, and institutions simultaneously: a genuinely difficult starting position for any new firm.

He describes the path through it as unglamorous but effective: consistently delivering value, prioritizing long-term relationships over one-off transactions, and forming real partnerships with leading incubators and academic institutions rather than operating at arm's length from the broader ecosystem.

That consistency, sustained over years, is what has helped build BIORx's reputation across India's innovation ecosystem: the foundation any firm needs before it can credibly claim global ambitions.

Gandhi's current profile reflects relationships with more than 40 incubators and innovation centres, including IIT Delhi, IIT Bombay, IIT Madras, IIT Kanpur, T-Hub, C-CAMP, BIRAC, IIMA Ventures, and AMTZ.

The Inflection Point

Gandhi points to the establishment of Indian Healthcare Angels as the moment BIORx's trajectory changed: pairing advisory expertise with a dedicated investor network built specifically for healthcare.

The scoreboard since then:  1,000+ startups impacted, 50+ invested portfolio companies, 30+ portfolio companies that have raised follow-on funding, 15+ M&A transactions facilitated, and mentorship and innovation relationships across 40-plus incubators and innovation centres.

IHA itself was created as a private platform for angel investors to access early-stage ventures, supported by a network of more than 1,000 senior CXO and industry leaders. Its stated vision is to become an ecosystem partner for the journey from idea to investment to exit.

That domestic foundation is precisely what makes BIORx's next chapter a genuinely global one:  a logical extension rather than a premature leap.

From India to the World

Gandhi's five-year vision is unambiguous about scale and geography: build one of India's most influential healthcare-focused investment platforms, one capable of enabling breakthrough Indian innovations to reach global markets.

That means expanding the investment portfolio, deepening cross-border collaborations, and facilitating larger fundraising and M&A transactions as the firm's portfolio companies mature into internationally competitive businesses.

It also means, in Gandhi's words, continuing to strengthen India's innovation ecosystem through mentorship, venture building, and strategic partnerships: treating the domestic and global ambitions as the same project rather than sequential ones.

His profile also reflects an M&A advisory role with Cross Border Associates, Germany, which is present in 106 countries, adding an international dimension to that ambition.

The Advice That Scales with the Ambition

For all the talk of global markets, Gandhi's advice to founders stays deliberately grounded:

"Focus on solving a real problem rather than simply building a product. Build a strong team, validate your solution with customers, stay resilient during setbacks, and continuously learn from mentors and industry experts. Fundraising is important, but creating sustainable value is even more critical. Success comes to entrepreneurs who remain patient, adaptable, and committed to execution."

It's a reminder that global ambition without a genuinely valuable underlying business is just a bigger version of the same mistake: the companies capable of competing internationally are, without exception, the ones that got the fundamentals right first.

Key Takeaways

· Global competitiveness starts with domestic infrastructure. 
You can't export what you haven't first built into an investable business.

· Sector depth beats geographic breadth, at first. 
BIORx built healthcare-specific credibility in India before positioning for global markets.

· Continuity from idea stage to scale-up builds cross-border readiness. 
Companies don't become globally competitive overnight; they're built toward it.

· Institutional trust takes years, not campaigns. 
Consistency across hundreds of engagements is what created BIORx's platform for global ambition.

· Fundamentals scale: hype doesn't. 
The advice that works for an early founder is the same advice that works at a global valuation.

A Closing Word

India's next global health-tech success stories are not likely to come from individual startups alone. Dr. Vishal Gandhi bets that building the infrastructure- mentorship, capital, strategic advisory, and cross-border deal-making- matters as much as any individual company's product.

If the next five years play out the way he envisions, India's place in the global healthcare innovation conversation may finally start to match its output.

To read more such stories visit Globally 24.